Publikationen

Bolenz, B. Schroppel, A. Eisenhardt, B. J. Schmitz-Drager and M. O. Grimm. In Reply. Dtsch Arztebl Int. 2019;116(11):192-193. doi: 10.3238/arztebl.2019.0192b. Epub 2019/04/25

Cella, V. Grunwald, B. Escudier, H. J. Hammers, S. George, P. Nathan, M. O. Grimm, B. I. Rini, J. Doan, C. Ivanescu, J. Paty, S. Mekan and R. J. Motzer. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. Lancet Oncol. 2019;20(2):297-310. doi: 10.1016/s1470-2045(18)30778-2. Epub 2019/01/20

F. Enderlein, T. Lehmann, F. C. von Rundstedt, R. Aschenbach, M. O. Grimm, U. Teichgraber and T. Franiel. Prostatic Artery Embolization-Anatomic Predictors of Technical Outcomes. J Vasc Interv Radiol. 2019. doi: 10.1016/j.jvir.2019.09.005. Epub 2019/11/19

Foller, H. Oppel-Heuchel and M. O. Grimm. [Tumor assessment in immune checkpoint inhibitor therapy : Tumor response, progression and pseudoprogression]. Urologe A. 2018;57(11):1316-1325. doi: 10.1007/s00120-018-0788-y. Epub 2018/10/20

J. Goebell, E. Hermann, U. Kube, C. Doehn, N. Marschner, A. Dietel, K. Blumenstengel, M. O. Grimm, M. Scheffler, A. Rogler and L. Bergmann. Final Results of a Non-Interventional Study Evaluating the Quality of Life in Second-line Treatment of Metastatic Renal Cell Carcinoma With Everolimus: The EVERPRO Study. Oncol Res Treat. 2019;42(1-2):57-66. doi: 10.1159/000494278. Epub 2019/01/21

O. Grimm. [Cytoreductive nephrectomy for metastatic renal cell carcinoma - obsolete?]. Urologe A. 2019;58(1):51-52. doi: 10.1007/s00120-018-0820-2. Epub 2018/12/06

O. Grimm, A. Bex, M. De Santis, B. Ljungberg, J. W. F. Catto, M. Roupret, S. A. Hussain, J. Bellmunt, T. Powles, M. Wirth and H. Van Poppel. Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019. Eur Urol. 2019;76(3):368-380. doi: 10.1016/j.eururo.2019.05.041. Epub 2019/06/27

Hesse-Macabata, B. Morgner, S. Morgenstern, M. O. Grimm, P. Elsner, U. C. Hipler and C. Wiegand. Innate immune response of human epidermal keratinocytes and dermal fibroblasts to in vitro incubation of Trichophyton benhamiae DSM 6916. J Eur Acad Dermatol Venereol. 2019;33(6):1177-1188. doi: 10.1111/jdv.15472. Epub 2019/02/06

Mai, M. Abubrig, T. Lehmann, T. Hilbert, E. Weiland, M. O. Grimm, U. Teichgraber and T. Franiel. T2 Mapping in Prostate Cancer. Invest Radiol. 2019;54(3):146-152. doi: 10.1097/rli.0000000000000520. Epub 2018/11/06

S. Michel, M. O. Grimm, M. Burger and F. Petersilie. [Promotion and support of successful training as a urologist by the Deutsche Gesellschaft fur Urologie]. Urologe A. 2019;58(2):139-142. doi: 10.1007/s00120-018-0846-5. Epub 2019/02/15

J. Motzer, B. I. Rini, D. F. McDermott, O. Aren Frontera, H. J. Hammers, M. A. Carducci, P. Salman, B. Escudier, B. Beuselinck, A. Amin, C. Porta, S. George, V. Neiman, S. Bracarda, S. S. Tykodi, P. Barthelemy, R. Leibowitz-Amit, E. R. Plimack, S. F. Oosting, B. Redman, B. Melichar, T. Powles, P. Nathan, S. Oudard, D. Pook, T. K. Choueiri, F. Donskov, M. O. Grimm, H. Gurney, D. Y. C. Heng, C. K. Kollmannsberger, M. R. Harrison, Y. Tomita, I. Duran, V. Grunwald, M. B. McHenry, S. Mekan and N. M. Tannir. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 2019;20(10):1370-1385. doi: 10.1016/s1470-2045(19)30413-9. Epub 2019/08/21

W. B. Piyarathna, T. M. Rajendiran, V. Putluri, V. Vantaku, T. Soni, F. C. von Rundstedt, S. R. Donepudi, F. Jin, S. Maity, C. R. Ambati, J. Dong, D. Godde, S. Roth, S. Storkel, S. Degener, G. Michailidis, S. P. Lerner, S. Pennathur, Y. Lotan, C. Coarfa, A. Sreekumar and N. Putluri. Erratum to "Distinct Lipidomic Landscapes Associated with Clinical Stages of Urothelial Cancer of the Bladder" [Eur Urol Focus 2018;4:907-915]. Eur Urol Focus. 2019;5(5):920. doi: 10.1016/j.euf.2019.08.010. Epub 2019/09/03

Retz, J. Bedke, M. Bogemann, M. O. Grimm, U. Zimmermann, L. Muller, C. Leiber, D. Teber, M. Wirth, C. Bolenz, R. van Alphen, M. De Santis, A. Beeker, J. Lehmann, M. Indorf, M. Frank, C. Bokemeyer and J. E. Gschwend. SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11). Eur J Cancer. 2019;107:37-45. doi: 10.1016/j.ejca.2018.11.001. Epub 2018/12/12

Stubendorff, K. Wilhelm, K. Posselt, J. Catto, A. Hartmann, S. Bertz, S. Fussel, V. Novotny, M. Toma, M. Gajda, J. Lehmann, H. Wunderlich, M. O. Grimm, M. Stockle and K. Junker. A three-gene methylation marker panel for the nodal metastatic risk assessment of muscle-invasive bladder cancer. J Cancer Res Clin Oncol. 2019;145(4):811-820. doi: 10.1007/s00432-018-02829-4. Epub 2019/01/04

Szabados, S. Foller, G. B. Schulz, M. Staehler, M. O. Grimm, C. G. Stief and J. Casuscelli. [Follow-up of renal cell carcinoma in a nonmetastatic stage]. Urologe A. 2019;58(1):65-76. doi: 10.1007/s00120-018-0823-z. Epub 2019/01/11

Tunger, U. Sommer, R. Wehner, A. S. Kubasch, M. O. Grimm, M. P. Bachmann, U. Platzbecker, M. Bornhauser, G. Baretton and M. Schmitz. The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy. J Clin Med. 2019;8(10). doi: 10.3390/jcm8101534. Epub 2019/09/29

Vantaku, J. Dong, C. R. Ambati, D. Perera, S. R. Donepudi, C. S. Amara, V. Putluri, S. S. Ravi, M. J. Robertson, D. W. B. Piyarathna, M. Villanueva, F. C. von Rundstedt, B. Karanam, L. Y. Ballester, M. K. Terris, R. J. Bollag, S. P. Lerner, A. B. Apolo, H. Villanueva, M. Lee, A. G. Sikora, Y. Lotan, A. Sreekumar, C. Coarfa and N. Putluri. Multi-omics Integration Analysis Robustly Predicts High-Grade Patient Survival and Identifies CPT1B Effect on Fatty Acid Metabolism in Bladder Cancer. Clin Cancer Res. 2019;25(12):3689-3701. doi: 10.1158/1078-0432.ccr-18-1515. Epub 2019/03/09

Vantaku, V. Putluri, D. A. Bader, S. Maity, J. Ma, J. M. Arnold, K. Rajapakshe, S. R. Donepudi, F. C. von Rundstedt, V. Devarakonda, J. Dubrulle, B. Karanam, S. E. McGuire, F. Stossi, A. K. Jain, C. Coarfa, Q. Cao, A. G. Sikora, H. Villanueva, S. M. Kavuri, Y. Lotan, A. Sreekumar and N. Putluri. Epigenetic loss of AOX1 expression via EZH2 leads to metabolic deregulations and promotes bladder cancer progression. Oncogene. 2019. doi: 10.1038/s41388-019-0902-7. Epub 2019/08/0

Zhang, D. Steinbach, M. O. Grimm and M. Horstmann. Utility of the EORTC risk tables and CUETO scoring model for predicting recurrence and progression in non-muscle-invasive bladder cancer patients treated with routine second transurethral resection. World J Urol. 2019;37(12):2699-2705. doi: 10.1007/s00345-019-02681-2. Epub 2019/03/27

Seitz C, Bach T, Bader M, Berg W, Knoll T, Neisius A, Netsch C, Nothacker M, Schmidt S, Schönthaler M, Siener R, Stein R, Straub M, Strohmaier W, Türk C, Volkmer B. [Update of the 2Sk guidelines on the diagnostics, treatment and metaphylaxis of urolithiasis (AWMF register number 043-025) : What is new?] Urologe A. 2019 Nov;58(11):1304-1312. doi: 10.1007/s00120-019-01033-7.

Böhm WU, Holstiege J, Wenzel S, Fahlenkamp D, Berg W. [Modern nephrolithiasis in the complex setting of metaphylaxis : Latest epidemiological data and a nationwide survey in private practices]. Urologe A. 2019 May;58(5):535-542. doi: 10.1007/s00120-019-0927-0.

Inhalt

Grimm MO, L¸mmen G. [Side effects of drug therapy in urology]. Urologe A. 2017.

Foller S, Oppel-Heuchel H, Fetter I, Winkler Y, Grimm MO. [Adverse events of immune checkpoint inhibitors]. Urologe A. 2017.

Horstmann M, Krause F, Steinbach D, Twelker L, Grimm MO. Evaluation of Plasmatic Kisspetin-10 as a Biomarker for Malignancy and Subtype Differentiation in Small Renal Tumours. Urol Int. 2017;98:177-83.

May M, Protzel C, Vetterlein MW, Gierth M, Noldus J, Karl A, et al. Is there evidence for a close connection between side of intravesical tumor location and ipsilateral lymphatic spread in lymph node-positive bladder cancer patients at radical cystectomy? Results of the PROMETRICS 2011 database. Int Urol Nephrol. 2017;49:247-54.

Roediger J, Hessenkemper W, Bartsch S, Manvelyan M, Huettner SS, Liehr T, et al. Supraphysiological androgen levels induce cellular senescence in human prostate cancer cells through the Src-Akt pathway. Mol Cancer. 2014;13:214.

Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18:312-22.

Grimm MO. [Immunooncology in Urologic Cancers: Current Status]. Aktuelle Urol. 2016;47:374-7.

Grimm MO. [Comment on: Focal therapy for small renal masses. Observation, ablation or surgery]. Urologe A. 2016;55:607-8.

Grimm MO, Winkler Y, Fetter I, Oppel-Heuchel H. [Renaissance of immuno-oncology for urological tumors : Current status]. Urologe A. 2016;55:621-6.

Oppel-Heuchel H, Grimm MO. [Therapy monitoring and management of adverse events in PD-1/PD-L1 immune checkpoint inhibition]. Urologe A. 2016;55:677-90.

Tanhaeivash R, Franiel T, Grimm MO, Horstmann M. Gigantic Suprapubic Lymphedema: A Case Study. World J Mens Health. 2016;34:148-52.

Winter BM, Gajda M, Grimm MO. [Diagnosis and treatment of retroperitoneal abscesses]. Urologe A. 2016;55:741-7.

Drozdz S, Schwedas M, Salz H, Foller S, Wendt TG. Prostate cancer treated with image-guided helical TomoTherapyÆ and image-guided LINAC-IMRT : Correlation between high-dose bladder volume, margin reduction, and genitourinary toxicity. Strahlenther Onkol. 2016;192:223-31.

Kasel-Seibert M, Lehmann T, Aschenbach R, Guettler FV, Abubrig M, Grimm MO, et al. Assessment of PI-RADS v2 for the Detection of Prostate Cancer. Eur J Radiol. 2016;85:726-31.

Assfalg V, H¸ser N, van Meel M, Haller B, Rahmel A, de Boer J, et al. High-urgency kidney transplantation in the Eurotransplant Kidney Allocation System: success or waste of organs? The Eurotransplant 15-year all-centre survey. Nephrol Dial Transplant. 2016;31:1515-22.

Dornbusch J, Walter M, Gottschalk A, Obaje A, Junker K, Ohlmann CH, et al. Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients. J Cancer Res Clin Oncol. 2016;142:1171-82.

Ergesi B, Winkler Y, Kistler T, Grimm MO, John H, Horstmann M. Prevalence and Management of Lower Urinary Tract Symptoms Related to Benign Prostatic Obstruction in a Contemporary Series of Renal Transplant Recipients. Nephrourol Mon. 2016;8:e35497.

Martini T, Gilfrich C, Mayr R, Burger M, Pycha A, Aziz A, et al. The Use of Neoadjuvant Chemotherapy in Patients With Urothelial Carcinoma of the Bladder: Current Practice Among Clinicians. Clin Genitourin Cancer. 2016.

Miller K, Albers P, Eichenauer R, Geiges G, Grimm MO, König F, et al. [Metastatic castration-resistant prostate cancer : Clinical data, new treatment options and therapy monitoring]. Urologe A. 2016;55:1206-12.

Franiel T, Asbach P, Teichgräber U, Hamm B, Foller S. Prostate Imaging--An Update. Rofo. 2015;187:751-9.

Metastatic castration-resistant prostate cancer: position paper for structured therapy monitoring
Miller K, Albers P, Eichenauer R, Geiges G, Grimm MO, König F, Mickisch G, Pfister D, Schwentner C, Suttmann H, Zastrow S.
Urologe A. 2014 May;53(5):710-4. doi: 10.1007/s00120-014-3491-7

Differential diagnosis of hematuria.
Horstmann M, Franiel T, Grimm MO.
Urologe A. 2014 Aug;53(8):1215-26. doi: 10.1007/s00120-014-3506-4

Evidence from the 'PROspective MulticEnTer RadIcal Cystectomy Series 2011 (PROMETRICS 2011)' Study: How are Preoperative Patient Characteristics Associated with Urinary Diversion Type After Radical Cystectomy for Bladder Cancer?
Schmid M, Rink M, Traumann M, Bastian PJ, Bartsch G, Ellinger J, Grimm MO, Hadaschik B, Haferkamp A, Hakenberg OW, Aziz A, Hartmann F, Herrmann E, Hohenfellner M, Janetschek G, Gierth M, Pahernik SH, Protzel C, Roigas J, Gördük M, Lusuardi L, May M, Trinh QD, Fisch M, Chun FK; PROMETRICS 2011 Research Group.
Ann Surg Oncol. 2014 Aug 28

A Natural Androgen Receptor Antagonist Induces Cellular Senescence in Prostate Cancer Cells.
Hessenkemper W, Roediger J, Bartsch S, Houtsmuller AB, van Royen ME, Petersen I, Grimm MO, Baniahmad A.
Mol Endocrinol. 2014 Sep 9:me20141170

Supraphysiological androgen levels induce cellular senescence in human prostate cancer cells through the Src-Akt pathway.
Roediger J, Hessenkemper W, Bartsch S, Manvelyan M, Huettner SS, Liehr T, Esmaeili M, Foller S, Petersen I, Grimm MO, Baniahmad A.
Mol Cancer. 2014 Sep 12;13:214. doi: 10.1186/1476-4598-13-214

An European Multicenter Randomized Noninferiority Trial Comparing 180-W GreenLight-XPS Laser Vaporization and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: 12-Months Results of the GOLIATH-study.
Bachmann A, Tubaro A, Barber N, d'Ancona F F, Muir G, Witzsch U, Grimm MO, Benejam J, Stolzenburg JU, Riddick A, Pahernik S, Roelink H, Ameye F, Saussine C, Bruyère F, Loidl W, Larner T, Gogoi NK, Hindley R, Muschter R, Thorpe A, Shrotri N, Graham S, Hamann M, Miller K, Schostak M, Capitán C, Knispel H, Thomas JA.
J Urol. 2014 Sep 11. pii: S0022-5347(14)04377-8. doi: 10.1016/j.juro.2014.09.001.

Placental Schistosoma haematobium infection in a German returnee from Malawi.
Schleenvoigt BT, Gajda M, Baier M, Groten T, Oppel-Heuchel H, Grimm MO, Pfister W, Richter J, Pletz MW.
Infection. 2014 Sep 19

Metastatic castration-resistant prostate cancer: position paper for structured therapy monitoring
Miller K1, Albers P, Eichenauer R, Geiges G, Grimm MO, König F, Mickisch G, Pfister D, Schwentner C, Suttmann H, Zastrow S.
Urologe A. 2014 May;53(5):710-4. doi: 10.1007/s00120-014-3491-7.

180-W XPS GreenLight laser vaporisation versus transurethral resection of the prostate for the treatment of benign prostatic obstruction: 6-month safety and efficacy results of a European Multicentre Randomised Trial--the GOLIATH study.
Bachmann A1, Tubaro A2, Barber N3, d'Ancona F4, Muir G5, Witzsch U6, Grimm MO7, Benejam J8, Stolzenburg JU9, Riddick A10, Pahernik S11, Roelink H12, Ameye F13, Saussine C14, Bruyère F15, Loidl W16, Larner T17, Gogoi NK18, Hindley R19, Muschter R20, Thorpe A21, Shrotri N22, Graham S23, Hamann M24, Miller K25, Schostak M26, Capitán C27, Knispel H28, Thomas JA29.
Eur Urol. 2014 May;65(5):931-42. doi: 10.1016/j.eururo.2013.10.040. Epub 2013 Nov 11.

Identification of high-risk patients with clear cell renal cell carcinoma based on interphase-FISH.
Sanjmyatav J, Matthes S, Muehr M, Sava D, Sternal M, Wunderlich H, Gajda M, Grimm MO, Junker K.
Br J Cancer. 2014 May 13;110(10):2537-43. doi: 10.1038/bjc.2014.159. Epub 2014 Mar 25.

Reply to Jérôme Verine, Christophe Leboeuf and Philippe Ratajczak's letter to the editor re: Jimsgene Sanjmyatav, Sven Hauke, Mieczyslaw Gajda, et al. Establishment of a multicolour fluorescence in situ hybridisation-based assay for subtyping of renal cell tumours. Eur Urol 2013;64:689-91.
Sanjmyatav J, Hartmann A, Moch H, Hauke S, Gajda M, Meyer B, Pryalukhin A, Grimm MO, Junker K.
Eur Urol. 2014 May;65(5):e71-2. doi: 10.1016/j.eururo.2013.12.002. Epub 2013 Dec 8. No abstract available.

MicroRNAs with prognostic potential for metastasis in clear cell renal cell carcinoma: a comparison of primary tumors and distant metastases.
Heinzelmann J, Unrein A, Wickmann U, Baumgart S, Stapf M, Szendroi A, Grimm MO, Gajda MR, Wunderlich H, Junker K.
Ann Surg Oncol. 2014 Mar;21(3):1046-54. doi: 10.1245/s10434-013-3361-3. Epub 2013 Nov 18.

Differentialdiagnose der Hämaturie
Horstmann M, Franiel T, Grimm MO
Der Urologe A. 2014 Aug;53(8):1215-26.

Prostatakarzinom
Franiel T, Eckardt N, Waginger M, Horstmann M
Der Radiologe, 2014 May;54(5):491-506

Prospective evaluation of fluorescence-guided cystoscopy to detect bladder cancer in a high-risk population: results from the UroScreen-Study
Horstmann M, Banek S, Gakis G, Todenhöfer T, Aufderklamm S, Hennenlotter J, Stenzl A, Schwentner C; UroScreen study group
2014 Jan 13;3:24. doi: 10.1186/2193-1801-3-24. eCollection 2014.

FISH analysis of washing urine from the upper urinary tract for the detection of urothelial cancers
Gruschwitz, T., Gajda, M., Enkelmann, A., Grimm, M.-O., Wunderlich, H., Horstmann, M.*, Junker, K.*, (*equally contributed)
Int Urol Nephrol. 2014 Apr 22. [Epub ahead of print]

Rud O, Horstmann M, Aziz A, Fritsche H M, Brookman-May S, Gilfrich C Burger M, May M      Prospective evaluation of intra-observer variability of the  hydronephrosis index in sonographic examination of 44 patients with acute renal colic, World J Urol. 2013. [Epub ahead of print]

Grimm MO, Hartmann F, Horstmann M, Operative Therapie des lokal begrenzten Prostatakarzinoms, Der Onkologe, Sept. 2013; 19 (9): S. 719-728

Galler K*, Junker K*, Franz M, Hentschel J, Richter P, Gajda M, Göhlert A, von Eggeling F, Heller R, Giavazzi R, Neri D, Kosmehl H, Wunderlich H, Berndt A (2011). Differential vascular expression and regulation of oncofetal tenascin-C and fibronectin variants in renal cell carcinoma (RCC): implications for an individualized angiogenesis-related targeted drug delivery. Histochem Cell Biol. 137(2):195-204 * equally contributed

Briest F, Berndt A, Clement J, Junker K, Eggeling F, Grimm S, Friedrich K (2012). Tumor-stroma interactions in tumorigenesis: lessons from stem cell biology. Front Biosci (Elite Ed). 4:1871-87

Stoehr CG, Stoehr R, Hartmann A, Hofstaedter F, Junker K, Blaszyk H, Wieland WF, Otto W, Denzinger S, Walter B (2011). Mutational activation of FGFR3: no involvement in the development of renal cell carcinoma. J Cancer Res Clin Oncol, 138(2):359-61

Steffens S, Janssen M, Roos FC, Becker F, Schumacher S, Seidel C, Wegener G, Thüroff JW, Hofmann R, Stöckle M, Siemer S, Schrader M, Hartmann A, Kuczyk MA, Junker K, Schrader AJ (2012). Eur J Cancer; in press

Junker K, Hartmann A, Stöckle M (2012). Therapy selection in patients with advanced bladder cancer : Is molecular biology helpful? Urologe A, 51(6):805-12

Walter B, Hartmann A, Hofstädter F, Junker K, Moch H, Bertz S, Denzinger S, Otto W, Gajda M, Stoehr CG (2012). Immunohistochemical marker panel differentiates between the three most common subtypes of renal cell carcinoma independent from histomorphologic criteria. Virchows Arch., 460(3):343-52

Junker K (2012). Foundation of the german network renal cell tumors association. Urologe A, 51(4):555-6.

Enkelmann A, Heinzelmann J, von Eggeling F, Walter M, Berndt A, Wunderlich H, Junker K (2011). J Cancer Res Clin Oncol. 137(5):751-9 

Sanjmyatav J, Steiner T, Wunderlich H, Diegmann J, Gajda M, Junker K. A specific gene expression signature characterizes metastatic potential in clear cell renal carcinomas (2011). J Urol. 2011 186(1):289-94 

Heinzelmann J, Henning B, Sanjmyatav J, Posorski N, Steiner T, Wunderlich H, Gajda MR, Junker K (2011). Specific miRNA signatures are associated with metastasis and poor prognosis in clear cell renal cell carcinoma. World J Urol. 29(3):367-73

Pilchowski R, Heinze C, Stöhr R, von Eggeling F, Hartmann A, Wunderlich H, Junker K (2011). Specific protein patterns characterize metastatic potential in advanced bladder cancer. J Urol 186(2):713-20

Voigt S, Hüttig F, Koch R, Propping S, Propping C, Grimm MO, Wirth M (2011). Risk factors for incidental prostate cancer-who should not undergo vaporization of the prostate for benign prostate hyperplasia? Prostate

Herrmann E, Marschner N, Grimm MO, Ohlmann CH, Hutzschenreuter U, Overkamp F, Groschek M, Blumenstengel K, Pühse G, Steiner T (2011). Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma. World J Urol.

Ploussard G, Epstein JI, Montironi R, Carroll PR, Wirth M, Grimm MO, Bjartell AS, Montorsi F, Freedland SJ, Erbersdobler A, van der Kwast TH (2011). The contemporary concept of significant versus insignificant prostate cancer. Eur Urol. 60(2):291-303.

Oosterwijk E, Rathmell WK, Junker K, Brannon AR, Pouliot F, Finley DS, Mulders PF, Kirkali Z, Uemura H, Belldegrun A (2011). Basic Research in Kidney Cancer. Eur Urol. [Epub ahead of print]

Junker K, Becker C, Wullich B (2011). Zukunftssicherung durch Forschung - Licht am Horizont? Urologe A. 2011 Aug;50(8):932-7

Gecks T, Junker K, Franz M, Richter P, Walther M, Voigt A, Neri D, Kosmehl H, Wunderlich H, Kiehntopf M, Berndt A (2011). B domain containing Tenascin-C: A new urine marker for surveillance of patients with urothelial carcinoma of the urinary bladder? Clin Chim Acta 412(21-22):1931-6

Wunderlich H, Brockmann JG, Voigt R, Rauchfuss F, Pascher A, Brose S, Binner C, Bittner H, Klar E (2011). DTG procurement guidelines in heart beating donors. Transpl Int. 24(7):733-57 

Kocot A, Giessing M, Fornara P, Engehausen D, Heynemann H, Wunderlich H, Dreikorn K, Riedmiller H (2011). [18th Annual Congress of the Renal Transplantation Working Group of the German Society of Urology: Würzburg, 18-20 November 2010]. Urologe A 50(7):846-9

Sanjmyatav J*; Junker K*; Matthes S; Muehr M; Sava D; Sternal M; Wessendorf S; Kreuz M; Gajda M; Wunderlich H; Schwaenen C (2011). Identification of Genomic Alterations Associated With Metastasis and cancer-specific survival in Clear Cell Renal Cell Carcinoma. J Urol. 186(5):2078-83

Galler K*, Junker K*, Franz M, Hentschel J, Richter P, Gajda M, Göhlert A, von Eggeling F, Heller R, Giavazzi R, Neri D, Kosmehl H, Wunderlich H, Berndt A (2011). Differential vascular expression and regulation of oncofetal tenascin-C and fibronectin variants in renal cell carcinoma (RCC): implications for an individualized angiogenesis-related targeted drug delivery. Histochem Cell Biol. [Epub ahead of print] * equally contributed

Berg W, Uhlemann C, Meißner A, Laube N (2011). Stress-related alteration of urine compositions : Idiopathic CaOx stone formers, patients with chronic inflammatory bowel disease (CIBD) and healthy controls. Urologe A

Wuttig D, Zastrow S, Füssel S, Toma MI, Meinhardt M, Kalman K, Junker K, Sanjmyatav J, Boll K, Hackermüller J, Rolle A, Grimm MO, Wirth MP (2011). CD31, EDNRB and TSPAN7 are promising prognostic markers in clear-cell renal cell carcinoma revealed by genome-wide expression analyses of primary tumors and metastases. Int J Cancer, in press

Berg W, Gayde S, Uhlemann C, Laube N (2010), Metabolic stress response patterns in urinary compositions of idiopathic calcium oxalate stone formers, patients with chronic bowel diseases and controls. Urol Res 38:161-168 

Chyhrai A, Sanjmyatav J, Gajda M, Reichelt O, Wunderlich H, Steiner T, Tanović E, Junker K (2010). Multi-colour FISH on preoperative renal tumour biopsies to confirm the diagnosis of uncertain renal masses. World J Urol 28(3):269-74  

Gruschwitz T, Breza J, Wunderlich H, Junker K (2010). Improvement of histopathological classification of adrenal gland tumors by genetic differentiation. World J Urol 28(3):329-34      

Escher N, Ernst G, Melle C, Berndt A, Clement JH, Junker K, Friedrich K, Guntinas-Lichius O, von Eggeling F (2010). Comparative proteomic analysis of normal and tumor stromal cells by tissue on chip based mass spectrometry (toc-MS). Diagn Pathol; 5:10. 

Kazarians B, Kausch I, Noack F, Junker K, Jocham D, Doehn C (2010). Atypical metastasis of renal cell carcinoma : Contribution of comparative genomic hybridisation to diagnosis. Urologe A 49(3):407-10

Sievert KD, Unteregger G, Nawroth R, Junker K, Becker C, Wullich B; Arbeitsgruppe urologische Forschung (AuF), Beratungs; Koordinierungsgremium des Vorstandes der Deutschen Gesellschaft für Urologie (DGU) (2010). Educational initiative of the German Society of Urology for innovative research : Workshops 2009. Urologe A. 2010 Jan;49(1):91-4

Enkelmann A, Heinzelmann J, von Eggeling F, Walter M, Berndt A, Wunderlich H, Junker K (2010). J Cancer Res Clin Oncol. 2010  

Hartmann A. Stöhr C, Junker K (2010). Hereditäre Nierenzellkarzinome. Pathologe  31:455-463

Kroeger N, M. Gajda, J. Zanow, I. Petersen, U. Settmacher, H. Wunderlich, T. Steiner (2010), Downsizing a Tumor Thrombus of Advanced Renal Cell Carcinoma with Neoadjuvant Systemic Therapy and Resulting Histopathological Effects, Urol Int. 84(4):479-84 

Steiner T, Kirchner H, Siebels M, Doehn C, Heynemann H, Varga Z, Rohde D, Schubert J, Jocham D, Stief C, Fornara P, Hofmann R, Loening S, Roigas J (2010). The role of surgery in clinical management of patients with metastatic papillary renal cell carcinoma. J Cancer Res Clin Oncol. 136: 905-10    

Schwarzer K, Foerster M, Steiner T, Hermann IM, Straube E (2010). BCG strain S4-Jena: An early BCG strain is capable to reduce the proliferation of bladder cancer cells by induction of apoptosis. Cancer Cell Int 29;10(1):21 

Ott U, Busch M, Steiner T, Wolf G  (2010). Presence of cardiovascular disease in patients on a waiting list for renal transplantation and in patients after kidney transplantation in a single center. Transplant Proc. 42(9):3450-4          

Walter M, Heinze C, Steiner T, Pilchowski R, von Eggeling F, Wunderlich H, Junker K (2010). Immunochemotherapy-associated protein patterns in tumour tissue and serum of patients with metastatic renal cell carcinoma. Arch Physiol Biochem 116(4-5):197-207

Berg W, Bechler R, Laube N (2009). Analytical precision of the Urolizer for the determination of the BONN-Risk-Index (BRI) for calcium oxalate urolithiasis and evaluation of the influence of 24-h urine storage at moderate temperatures on BRI. Clin Chem Lab Med 47(4):478-82.

Berg W, Bechler R, Haas C, Laube N (2009). Relevance of the BONN Risk Index for metabolic monitoring of patients with calcium oxalate urolithiasis: a clinical application study of the Urolizer. Urol Res 37(2):55-62

Amin MB, Gupta R, Ondrej H, McKenney JK, Michal M, Young AN, Paner GP, Junker K, Epstein JI (2009). Primary thyroid-like follicular carcinoma of the kidney: report of 6 cases of a histologically distinctive adult renal epithelial neoplasm. Am J Surg Pathol. 33(3):393-400

Eichelberg C, Junker K, Ljungberg B, Moch H (2009). Diagnostic and Prognostic Molecular Markers for Renal Cell Carcinoma: A Critical Appraisal of the Current State of Research and Clinical Applicability. Eur Urol. 55(4):851-63

Richter P, Tost M, Franz M, Altendorf-Hofmann A, Junker K, Borsi L, Neri D, Kosmehl H, Wunderlich H, Berndt A (2009). B and C domain containing tenascin-C: urinary markers for invasiveness of urothelial carcinoma of the urinary bladder? J Cancer Res Clin Oncol.

Junker K, Steiner T, Sanjmyatav J, Pilchowski R, Heinze C, Walter M, Schubert J. (2009). Tumor profiling of renal cell tumors: relevance for diagnostics and therapy. Pathologe. 30(2):105-10.

Steiner T, Boehme C, Wolf G, Schubert J, Ott U (2009). Impact of immunologic and nonimmunologic variables on long-term outcome after kidney transplantation. Transplant Proc.6: 2521-3

Fechner G, Müller SC, Küster J, Dreikorn K, Steiner T, Giessing M (2009). 16th Annual Conference of the Working Group for Kidney Transplantation of the Academy of German Urologists. Bonn, 6th-8th November 2008. Urologe A 48(3): 296-8.

Steiner T, Wunderlich H, Ott U (2009). Sexuality after kidney transplantation. Urologe A 12: 1438-1442

Wutzler U, Venner M, Villmann T, Decker O, Ott U, Steiner T, Gumz A. Recording of dissimulation and denial in the context of the psychosomatic evaluation at living kidney transplantation using the Minnesota Multiphasic Personality Inventory (MMPI). Psychosoc Med. 6: 1-11

Steiner T, Steiner C, Klemm P (2009) Urological diseases during pregnancy. Der Nephrologe 4(4): 334-338

Gruschwitz, T., Stein R, Schubert J, Wunderlich H (2008). Laser - supported partial nephrectomy. Urology 71(2):334.336

Gruschwitz T, Schubert J, Wunderlich H (2008). Lasergestützte partielle Nephrektomie beim Nierenzellkarzinom. Urologe A 47(9):1173-4

Junker K, van Oers JMM, Zwarthoff E, Kania I, Schubert J, Hartmann A (2008). FGFR3 mutations in bladder tumors correlate with low frequency of chromosome alterations. Neoplasia, 10(1): 1-7

Richter P*, Junker K*, Franz M, Berndt A, Geyer C, Gajda M, Kosmehl H, Berndt A, Wunderlich H (2008). IIICS de novo glycosylated fibronectin as a marker for invasiveness in urothelial carcinoma of the urinary bladder (UBC). J Cancer Res Clin Oncol.  * equally contributed

Junker K, Sanjmyatav J, Heinze C, Walter M, Heinzelmann J, Wunderlich H, Schubert J, Steiner T (2008). Molecular characterization of metastatic renal cell carcinomas : Differentiation of prognosis and therapy. Urologe A. 47(9):1187-9.

Junker K, Wunderlich H, Steiner T, Hartmann A, Schubert J (2008). The german renal cell tumor network. Urologe A 47(9):1171-2

Stenzl A, Jocham D, Jichlinski P,  Junker K, König F, van den Bergh H, Volkmer B, Zaak D, Gschwend JE. Photodynamic diagnostics in the urinary tract : Consensus paper of the Working Group for Oncology of the German Society for Urology. Urologe A 47(8):982-7

Huse K, Taudien S, Groth M, Rosenstiel P, Szafranski K, Hiller M, Hampe J, Junker K, Schubert J, Schreiber S, Birkenmeier G, Krawczak M, Platzer M (2008). Genetic Variants of the Copy Number Polymorphic beta-Defensin Locus Are Associated with Sporadic Prostate Cancer. Tumour Biol 29(2):83-92

Amin MB, Gupta R, Ondrej H, McKenney JK, Michal M, Young AN, Paner GP, Junker K, Epstein JI (2008). Primary Thyroid-like Follicular Carcinoma of the Kidney: Report of 6 Cases of a Histologically Distinctive Adult Renal Epithelial Neoplasm. Am J Surg Pathol. 2008

Reichelt O, Borkowetz A, Chyhrai A, Tanovic E, Weirich T, Müller T, Schubert H, Schubert J (2008). Preparation for clinical introduction of advanced laparoscopic procedures : Laparoscopic renal autotransplantation. Urologe A 47(10):1339-46

Ott U, Busch M, Steiner Th, Schubert J, Gröne E, Gröne HJ, Wolf G (2008) Bilateral xanthogranulomatous pyelonephritis - a rare disease with severe consequences for renal function. Kidney international 73: 787-788

Ott U, Busch M, Steiner Th, Schubert J, Wolf G (2008) Renal Retransplantation - A retrospective monocentric study. Transplantation Proceedings 40: 1345-1348

Steiner Th (2008) Kein einheitliches Vorgehen” - Kommentar zur Arbeit: Weniger Komplikationen durch ureterale Stents bei Nierentransplantation. Aktuelle Urologie 39(1): 4-6

Steiner Th, Schubert J, Wolf G, Giessing M (2008) 15. Jahrestagung des Arbeitskreises Nierentransplantation der Akademie der Deutschen Urologen. Der Urologe 47: 486-488

Ott U, Steiner Th, Busch M, Gerth J, Wolf G (2008) A single-center experience with BK virus nephropathy. Clinical Nephrology 69 (4); 2008: 244-250

Henkel R, Schreiber G, Sturmhoefel A, Hipler U, Zermann DH, Menkveld R (2008). Comparison of three staining methods for the morphological evaluation of human spermatozoa. Fertil Steril

Ott U, Busch M, Steiner T, Wolf G (2008) Anemia after renal transplantation: An underestimated problem. Transplantation Proceedings 40: 3481-3484

Voigt S, Grimm MO, Wirth M. Regulation der Ausschüttung von Geschlechtshormonen und Wirkmechanismen der antiandrogenen Hormontherapie. In: Androgenblockade beim hormonabhängigen Prostatakarzinom. Uni-Med Verlag AG 2011; S. 18-28

Junker K, Sanjmyatav J, von Eggeling F. Identifikation molekularer Targets. In: Molekulare Therapie bei urologischen Tumoren. Uni-Med Verlag AG 2008; S. 20-29

Steiner Th, Gummert J, Settmacher U, Wolf G, Schubert J. Historie - Stand - Perspektiven der Transplantationsmedizin am UK Jena. In Vitalprinzip Akademie - Festgabe der Akademie gemeinnütziger Wissenschaften zu Erfurt zur 450-Jahrfeier der Friedrich-Schiller-Universität Jena. Herausgeber: Präsidium der Akademie gemeinnütziger Wissenschaften zu Erfurt: W. Köhler, K. Manger, H.-P. Klöcking, J. Kiefer. Verlag der Akademie gemeinnütziger Wissenschaften zu Erfurt; 2008; S. 397-403

Steiner Th. Vom Labor in die Klinik - Substanzklassen und Wirkstoffe in der molekularen Therapie. In Molekulare Therapie bei urologischen Tumoren. Herausgeber: J. Roigas, M. Johannsen, M. Ringsdorf, A. Römer. UNI-MED Verlag Bremen - London - Boston; 2008; S. 30 - 35